Global Biosimulation Market Expected to Witness a CAGR of 15.9% During the Forecast Period 2018-2023 - ResearchAndMarkets.com

DUBLIN--()--The "Global Biosimulation Market - Segmented by Application and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

Market Drivers

The development of new drugs require a huge amount of research and resources. Drug discovery involves enormous investment, and the failure of drug molecule in the later phase results in wastage of effort and cost. Hence, there was a necessity to develop a tool that will outlay the future drug molecule, during the discovery phase.

Biosimulation not only helps in predicting the chances of failure of a drug in the development process, but also reduces the cost of any other possible failures by shrinking the set of clinical experiments. This is the major reason that drives the growth of the global biosimulation market. The need for low drug discovery and less development cost is expected to drive this market with a high growth rate in future.

The other factors supporting the growth of the market is the increased accuracy of prediction before an actual trial and increasing healthcare expenditure along with technological advancements in the field of biosimulation.

Market Restraints

Professionals working in the biosimulation market have to possess comprehensive knowledge about the software and science involved in the drug development. Hence the pharmaceutical industry is lacking qualified experts working in this field, and they are looking forward to train their employees, which may consume time and resources. Therefore, the shortage of trained professionals is a limiting factor for the biosimulation market.

Key Developments in the Market

  • July 2017: EQT Partners Inc. acquired Certara, which is a continuation of the convergence between healthcare and technology, as the industry further adopts biosimulation to advance drug development.

Key Topics Covered

1. Introduction

1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

5.1 Current Market Scenario

5.2 Porter's Five Forces Analysis

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

6.1 Market Drivers

6.2 Market Restraints

6.3 Opportunities

6.4 Key Challenges

7. Market Segmentation

7.1 By Application

7.2 By Geography

8. Competitive Landscape

8.1 Mergers and Acquisition Analysis

8.2 Agreements, Collaborations, and Partnerships

8.3 New Products Launches

9. Key Players

9.1 Rhenovia Pharma

9.2 Accelrys

9.3 Certara

9.4 Genedata

9.5 Leadscope

9.6 Compugen

9.7 Archimedes

9.8 Simulations Plus Inc.

9.9 Schrodinger Inc.

9.10 Insilico BioTechnology

9.11 List Not Exhaustive

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/mprrf9/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery